Product category:
Antibodies
News Release from: AbD Serotec
Edited by the Laboratorytalk Editorial
Team on 19 April 2005
Agreement covers antibodies and peptides
Co-marketing agreement covering the rapid generation of monoclonal antibodies and complementary peptide-based services and products
Antibodies by Design and JPT Peptide Technologies have started a co-marketing agreement covering the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan
This article was originally published on Laboratorytalk on 2 Dec 2004 at 8.00am (UK)
Related stories
Announcing the first recombinant antibody
Said to be the first in vitro derived recombinant antibody, it is targeted against Cyclophilin A, which is indicated to play an important role in the mechanism of protein folding
"We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers", stated Dieter Lingelbach, head of the Antibodies by Design division and senior vice president of MorphoSys.
"Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe".
"MorphoSys's unique antibody repertoire is the ideal complement to our immunology tools programme which includes the peptide array platforms PepSpot and PepStar plus the novel PepMix technology for effective T-lymphocyte stimulation.
"This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services", said Holger Wenschuh, managing director of JPT.
• AbD Serotec: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
